Go to Health Care Provider version
| Diagnosis | High Grade Glioma, Replication Repair Deficient | Study Status | Open |
| Phase | N/A |
| Age | 12 Months to 25 Years | Randomisation | NO |
| Line of treatment | First line treatment |
| Routes of Treatment Administration | Drug: Nivolumab
All patients will be administered Nivolumab with or without radiation |
| Last Posted Update | 2024-12-12 |
| ClinicalTrials.gov # | NCT06519682 |
International Sponsor
The Hospital for Sick ChildrenPrincipal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Uri TaboriCentres
Study Description
This study is eligible for STEP-1 funding. Find more information here.
This study is eligible for STEP-1 funding. Find more information here.
This study is testing a medicine called nivolumab for people with a type of brain cancer called RRD-glioblastoma. The goal is to see if this medicine can help delay or avoid the need for radiation treatment.
Inclusion Criteria
- Patient must be between 1 and 25 years old.
- Must have glioblastoma, confirmed by a biopsy
- Tumor must show certain genetic changes linked to RRD, confirmed by tests on the tumour
- A sample of the tumor is needed for analysis, and another sample may be required if the tumor grows back
- Most or all of the tumor must have been removed in surgery, and treatment should start within 4 weeks after surgery.
- No treatments (like chemotherapy or radiation) for glioblastoma are allowed before the study, but surgery is okay. Past treatment for other cancers is allowed if previous cancer is in remission
- Must have good overall health, including healthy organs and no serious infections
- Participants and their families must agree to join the study
Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.
